Background: Post hoc analysis of clinical trials shows blood eosinophil counts (BEC) predict future preschool wheeze attacks; however, prospective usefulness in a clinical setting is unreported. We assessed the feasibility of point-of-care (POC) eosinophil measurements in preschool wheezers and related BEC to symptoms, lung function, and utility in predicting attacks.
Methods: Children aged 1-5 years with recurrent wheeze underwent finger-prick sampling during the outpatient clinic for POC eosinophils, forced oscillation technique (FOT) and/or spirometry, and symptom score (TRACK questionnaire). The utility of BEC and/or the other tests in predicting wheeze attacks in the subsequent 3 months was analysed by comparing those with and without an attack and using a predictive decision tree (DT) model.
Results: Seventy-three children (median age 4.27 years) were recruited; BEC were higher in atopic children (median 0.5 × 10/L vs. 0.3 × 10/L non-atopic, p < 0.01). BEC moderately correlated with FOT reactance bronchodilator reversibility z-score changes (r = 0.495, p = 0.005), but no other lung function measures or TRACK score. 68/73 (93%) children were followed up at 3 months. 29/68 (43%) children had > 1 wheeze attack requiring unscheduled healthcare attendance. Absolute and %eosinophils at the baseline visit were higher in those who had an attack (median 0.5 × 10/L vs. 0.3 × 10/L, p = 0.03 and median 6% vs. 4%, p < 0.01). The DT model showed children with BEC ≥ 4% and TRACK score < 75 were more likely to have a future attack (probability 0.63).
Conclusion: POC blood eosinophils were feasible in a clinical setting. Our preliminary data suggest elevated BEC with a low symptom score predicts a wheeze attack within 3 months.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.16500 | DOI Listing |
Allergy
February 2025
National Heart & Lung Institute, Imperial College London, London, UK.
Background: Post hoc analysis of clinical trials shows blood eosinophil counts (BEC) predict future preschool wheeze attacks; however, prospective usefulness in a clinical setting is unreported. We assessed the feasibility of point-of-care (POC) eosinophil measurements in preschool wheezers and related BEC to symptoms, lung function, and utility in predicting attacks.
Methods: Children aged 1-5 years with recurrent wheeze underwent finger-prick sampling during the outpatient clinic for POC eosinophils, forced oscillation technique (FOT) and/or spirometry, and symptom score (TRACK questionnaire).
Curr Opin Pulm Med
February 2025
National Heart and Lung Institute, Imperial College, and Imperial Centre for Paediatrics and Child Health, Consultant Paediatric Chest Physician, Royal Brompton Hospital, London, UK.
Purpose Of Review: The field of paediatric asthma is rapidly moving, with the advent of new biologicals for severe asthma and increased understanding of preschool wheeze amongst other developments and insights.
Recent Findings: There is increasing evidence of efficacy in children for biologics directed against Type 2 inflammation (especially mepolizumab and dupilumab) as well encouraging evidence that Tezepelumab may be effective against Type 2 low phenotypes. The importance of airway remodelling and infection in the pathophysiology of preschool wheeze is increasingly appreciated.
J Assoc Physicians India
January 2025
Professor and Head, Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India, Orcid: https://orcid.org/0000-0001-7520-5404, Corresponding Author.
Asthma is a long-term, persistent disease characterized by inflammation in the lower airways. Patients with asthma can be of any age, from young children to elderly people, and present with various clinical manifestations such as chest tightness, wheezing, coughing, and difficulty in breathing. Distinguishing these variations is essential for the personalized and adequate management of the disease.
View Article and Find Full Text PDFIntroduction: Patients with uncontrolled, moderate-to-severe asthma have a higher risk for exacerbations, negatively impacting lung function and quality of life. Dupilumab, a fully human monoclonal antibody, blocks interleukins 4 and 13, key and central drivers of type 2 inflammation. Dupilumab has been effective in the treatment of certain types of moderate-to-severe asthma across several clinical trials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!